噻吩并吡啶类抗血小板聚集药物研究概况

被引:16
作者
卜晓斐 [1 ,2 ]
刘鹏 [2 ]
付晓丽 [2 ]
徐为人 [1 ,2 ]
机构
[1] 天津中医药大学
[2] 天津药物研究院天津市新药设计与发现重点实验室
关键词
噻吩并吡啶类药物; 噻氯匹定; 氯吡格雷; 普拉格雷; 二磷酸腺苷受体;
D O I
暂无
中图分类号
R973.2 [];
学科分类号
摘要
心脑血管疾病严重威胁人类健康,抗血小板治疗已经被证明可以有效预防和改善心脑血管疾病。噻吩并吡啶类药物是以二磷酸腺苷受体为靶点的一类抗血小板药物,包括噻氯匹定、氯吡格雷和普拉格雷,是目前临床上应用最为广泛、有效的抗血小板聚集、抗血栓药物,极大地改善了全球心脑血管患者的健康状况。概括介绍噻吩并吡啶类药物的代谢与起效模式、作用机制、临床应用及药物相互作用等方面的研究进展。
引用
收藏
页码:43 / 48
页数:6
相关论文
共 10 条
[1]
Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators [J].
Harjai, Kishore J. ;
Shenoy, Chetan ;
Orshaw, Pam ;
Usmani, Samer ;
Boura, Judy ;
Mehta, Rajendra H. .
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (02) :162-170
[2]
Antiplatelet drug interactions [J].
Mackenzie, I. S. ;
Coughtrie, M. W. H. ;
MacDonald, T. M. ;
Wei, L. .
JOURNAL OF INTERNAL MEDICINE, 2010, 268 (06) :516-529
[3]
Patients With Previous Definite Stent Thrombosis Have a Reduced Antiplatelet Effect of Aspirin and a Larger Fraction of Immature Platelets [J].
Wurtz, Morten ;
Grove, Erik L. ;
Wulff, Lise N. ;
Kaltoft, Anne K. ;
Tilsted, Hans H. ;
Jensen, Lisette O. ;
Hvas, Anne-Mette ;
Kristensen, Steen D. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (08) :828-835
[4]
Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome [J].
Rassen, Jeremy A. ;
Choudhry, Niteesh K. ;
Avorn, Jerry ;
Schneeweiss, Sebastian .
CIRCULATION, 2009, 120 (23) :2322-U34
[5]
Advances in Antiplatelet Therapy: Agents in Clinical Development.[J].Dominick J. Angiolillo;Deepak L. Bhatt;Paul A. Gurbel;Lisa K. Jennings.The American Journal of Cardiology.2009, 3
[6]
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel [J].
Juurlink, David N. ;
Gomes, Tara ;
Ko, Dennis T. ;
Szmitko, Paul E. ;
Austin, Peter C. ;
Tu, Jack V. ;
Henry, David A. ;
Kopp, Alex ;
Mamdani, Muhammad M. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2009, 180 (07) :713-718
[7]
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors [J].
Pezalla, Edmund ;
Day, David ;
Pulliadath, Indira .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (12) :1038-1039
[8]
Prasugrel: A novel antiplatelet agent [J].
Riley, Amy B. ;
Tafreshi, Mohammad J. ;
Haber, Stacy L. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (11) :1019-1028
[9]
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R).: Rationale for the study and protocol design [J].
Valgimigli, Marco ;
Campo, Gianluca ;
de Cesare, Nicoletta ;
Vranckx, Pascal ;
Hamon, Martial ;
Angiolillo, Dominick J. ;
Sabate, Manel ;
Ferrari, Fabrizio ;
Furgieri, Alessandro ;
Tumscitz, Carlo ;
Repetto, Alessandra ;
Colangelo, Salvatore ;
Meliga, Emanuele ;
Kubbajeh, Moh'd ;
Parrinello, Giovanni ;
Percoco, Gianfranco ;
Ferrari, Roberto .
CARDIOVASCULAR DRUGS AND THERAPY, 2008, 22 (04) :313-320
[10]
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study [J].
Angiolillo, Dominick J. ;
Shoemaker, Steven B. ;
Desai, Bhaloo ;
Yuan, Hang ;
Charlton, Ronald K. ;
Bernardo, Esther ;
Zenni, Martin M. ;
Guzman, Luis A. ;
Bass, Theodore A. ;
Costa, Marco A. .
CIRCULATION, 2007, 115 (06) :708-716